TGFB1 and neoplasm: Next to supporting therapy resistance, certain CAFs in advanced CRCs can actively contribute to immune evasion of tumor cells (e.g., via aberrant TGF-β signaling [131]) and inhibition of anti-tumor immune responses [132,133,134,135].